Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A drug to treat inflammation plays a surprising role in reducing the level of infection caused by an opportunistic bug that is deadly for HIVers and cancer patients and other people with weakened immune systems.
[ WELLNESS WEDNESDAY ]
The drug — sulfasalazine — spurs the body to get rid of the fungal evaders by enhancing the body's ability to chew them up instead of leaving the debris to litter the lungs, where it would continue to provoke an onslaught of harmful inflammation.Besides opening a new avenue for research on Pneumocystis pneumonia, caused by the fungus Pneumocystis jirovecii, the work with mice also offers the possibility of manipulating immune cells called macrophages to improve treatment of infections.
The findings by scientists at the University of Rochester Medical Center were published August 19 in the journal PLoS Pathogens.
During a bout with pneumocystosis, the lungs become a battlefield, where the body pits an array of impressive forces against marauding microbes. But even when the body gets the upper hand, the damage is tremendous. Immune cells like neutrophils and macrophages can flood the lungs, literally suffocating the patient. And when the debris from dead microbes fills the lungs, more and more immune cells are called in to clean up the area, making matters worse. It becomes harder and harder to breathe.
"Many people assume that once the microbe is dead, patients usually start to feel better immediately. But with Pneumocystis, patients do not always undergo a rapid clinical improvement following antibiotic treatment. Even though the bug has been killed, the debris that is left in the lungs continues to promote inflammation," said Terry Wright, Ph.D., an infectious disease specialist and associate professor of microbiology and immunology and of pediatrics.
Pneumocystis is a common bug that infects nearly everyone at some point; the authors say that more than 80% of children have been infected by the age of 2. Most people shake off the infection without consequence, but for people with cancer, AIDS, or other diseases that compromise their immune system, the infection can be deadly. Usually there are few signs that the patient is sick until the infection is well established and the fungus is widespread in the lungs. Among cancer patients, mortality rates as high as 40% have been reported.
Since the body's immune response is central to how Pneumocystis kills patients, doctors use two different types of drugs in tandem to treat patients — an antibiotic to kill the bug and steroids or another type of drug to reduce the consequent inflammation.
Central to the study were mice in which the disease progresses in a manner very similar to AIDS patients. The remarkable strides in AIDS therapy in recent years have come with a downside for many patients, thanks to Pneumocystis. When antiretroviral therapy kicks in, a patient's immune system often becomes stronger very quickly — and if the fungus is present, the immune system attacks it vigorously, causing a potentially deadly form of pneumonia.
Wright's team looked at the effects in mice of sulfasalazine, an anti-inflammatory drug that has proved useful in treating conditions like Crohn's disease and rheumatoid arthritis. The team found that Pneumocystis-infected mice treated with sulfasalazine developed much less severe disease than untreated mice. The sulfasalazine-treated mice had better lung function, less weight loss, and were generally healthier than untreated animals.
While some of the benefit was due to the drug's anti-inflammatory properties and was expected, the result included a big surprise; the drug also spurs the body to remove the bug more aggressively by boosting the activity of immune cells called macrophages.
"This was unexpected," said Jing Wang, Ph.D., research assistant professor in pediatrics. "Since we reduced the response of the immune system, you would think the mice would get sicker. But instead, the mice treated with sulfasalazine were healthier. At first we thought it was due solely to the anti-inflammatory activity of the compound, but it turns out that sulfasalazine actually results in a reduced fungal burden. The drug helps the body clear the infection.
"We initially thought we had done something wrong, and so we repeated the experiment again and again. Then, when new technology was developed, we were able to document that the body cleared the infection more readily with sulfasalazine," Wang added.
Scientists have long known that the body's immune T cells are central to the body's response to fight off the infection. The Rochester team showed that the body's T cells spur macrophages to attack the fungus — to engulf its particles and chew them up in a process known as phagocytosis.
While scientists have long suspected that role for macrophages, the Rochester team relied on a new technology to gather the first direct evidence of macrophages engulfing fungal particles. The scientists worked closely with Timothy Bushnell, Ph.D., and others at Rochester's Flow Cytometry Resources Core, investigating new ways to use lasers to capture images of molecular events. Bushnell's team ultimately connected the team with scientists at Amnis. Together the group developed a new way to capture macrophage phagocytosis in single cells from mice infected with Pneumocystis. The technology enabled the team to capture more than 40,000 such events, compared to just a handful when using conventional microscopy.
The team showed that as macrophage activity increased, the animals' health improved and levels of fungus decreased. For example, 17 days after infection, mice treated with sulfasalazine had nine times as many macrophages that had engulfed fungal particles compared to mice that had not been treated with the compound.
"This marks a new direction in which to look for new therapies to treat Pneumocystis as well as other inflammatory diseases. Identifying modulators that can increase or decrease the action of our immune system in a precise manner is a growing area of research," Wright said. Recently researchers have come to realize that there are different kinds of macrophages, and Wright noted that the type whose activity is trigged by sulfasalazine does not contribute to inflammation.
From our Sponsors
Most Popular
Why activist Raif Derrazi thinks his HIV diagnosis is a gift
September 17 2024 12:00 PM
Out100 Honoree Tony Valenzuela thanks queer and trans communities for support in his HIV journey
September 18 2024 12:00 PM
How fitness coach Tyriek Taylor reclaims his power from HIV with self-commitment
September 19 2024 12:00 PM
Creator and host Karl Schmid fights HIV stigma with knowledge
September 12 2024 12:03 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
Plus: Featured Video
Latest Stories
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
SFAF's Dr. Tyler TerMeer says he'll continue to fight for health care for all
January 28 2025 3:00 PM
Lexi Love goes public with HIV status after Trump wipes resources from federal website
January 23 2025 11:23 AM
Plus nominated for 2025 GLAAD Media Award alongside industry giants like Vogue, People, and Variety
January 22 2025 12:42 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM
Check out our 2024 year-end issue!
October 28 2024 2:08 PM
Meet our Health Hero of the Year, Armonté Butler
October 21 2024 12:53 PM
AIDS/LifeCycle is ending after more than 30 years
October 17 2024 12:40 PM
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
October 15 2024 5:03 PM
Kentucky bans conversion therapy for youth as Gov. Andy Beshear signs 'monumental' order
September 18 2024 11:13 AM
Study finds use of puberty blockers safe and reversible, countering anti-trans accusations
September 11 2024 1:11 PM
Latinx health tips / Consejos de salud para latinos (in English & en espanol)
September 10 2024 4:29 PM